Pfizer/Ligand Fablyn delayed
Executive Summary
FDA issues "complete response" letter for Pfizer/Ligand's osteoporosis drug Fablyn (lasofoxifene) Jan. 16. FDA has expressed concern with an apparent increase in mortality among Fablyn patients. FDA's Reproductive Health Drugs Advisory Committee found that trend to be inconclusive during a Sept. 8 meeting, and voted 9-3 (with one abstention) that there was a population of post-menopausal women with osteoporosis for which the use of Fablyn outweighed the risks (1"The Pink Sheet," Sept. 15, 2008, p. 3). Pfizer proposed a 50,000-patient post-marketing safety cohort study to help resolve the issue
You may also be interested in...
Fablyn Panel Finds Mortality Trend Inconclusive, But Pfizer Ready With A Plan
FDA's Advisory Committee for Reproductive Health Drugs did not reach a clear conclusion on whether Pfizer's osteoporosis drug Fablyn has a mortality issue - but Pfizer already has a proposal for a post-market study to provide a definitive answer
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.